The treatment, still in clinical trials, has shown signs of becoming one of the first gene therapies that actually works.
The first wave of clinical trials has shown that in general such vaccination strategies are safe.
Analysis of previous trials has shown that H+ISDN appears especially beneficial in African American patients.
Baclofen is a GABAB receptor agonist that in preclinical and early pilot clinical trials has shown promise for the treatment of cocaine dependence.
In addition, experience in human trials has shown that induction of capsid-specific CD8+ T cell responses can lead to clearance of AAV vector-transduced cells3,5,6,17.
A handful of small-scale clinical trials has shown that some patients benefit from using TMS either to reduce the frequency or diminish the intensity of migraine attacks.
Recent evidence from several randomized trials has shown that adjuvant chemotherapy regimens of platinum-based agents plus third-generation cytotoxic agents improve survival rates in this population of patients.
The Ebola outbreak in the DRC is benefiting from clinical research, as a vaccine in late-stage trials has shown to be effective and is being employed through compassionate use protocols to attempt to stem transmission and vaccinate at-risk populations, such as health workers.
None of these trials has shown evidence for efficacy of any agents tested, including retinol (vitamin A), β-carotene, N-acetylcysteine, and selenium.
A recently published systematic Cochrane review of randomized controlled trials has shown the efficacy of NSAIDs and COX-2 inhibitors in the treatment of nonspecific low-back pain.
Evidence from randomized clinical trials has shown that babies born to women who double their recommended daily dose of folic acid are between 40% and 50% less likely to have birth defects of the spine, skull, and brain.
